OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SFZN59

Siegfried Holding AG

PharmaceuticalsVerified

Siegfried's capital structure is relatively balanced, with a debt-to-equity ratio of 0.51, indicating moderate leverage. The company maintains a current ratio of 2.0, suggesting it has sufficient short-term liquidity to cover its obligations. However, its free cash flow of CHF 15.04 million is relatively low compared to its operating cash flow of CHF 228.16 million, indicating that capital expenditures are consuming a significant portion of its operating cash. In terms of profitability, Siegfried's return on equity (ROE) of 14.95% and return on assets (ROA) of 7.83% are strong, but they should be compared to the industry median to determine relative performance. The company's gross profit margin of 26.66% (CHF 353.99 million gross profit on CHF 1.33 billion revenue) is a key indicator of its pricing power and cost control. Siegfried's operating margin of 16.85% (CHF 223.76 million operating income) is also robust, but again, a comparison to industry peers is necessary to assess its competitive position. Geographically, Siegfried's revenue is concentrated in Europe, with no specific breakdown provided in the available data. The company's exposure to this region may present both opportunities and risks, particularly in light of regulatory changes and currency fluctuations. Siegfried operates in a single business segment, which simplifies its operations but also means that its performance is entirely dependent on the pharmaceuticals market. Looking ahead, Siegfried's growth trajectory is expected to be modest, with no specific numeric deltas provided for the current or next fiscal year. The company's capital expenditures of CHF 231.47 million are a significant outflow, which may impact its ability to reinvest in growth opportunities. Analysts have a generally positive outlook, with a mean recommendation of 2.10 (on a scale from 1 to 5) and a mean price target of CHF 104.00. Siegfried faces several risk factors, including liquidity concerns due to its negative net cash position after subtracting total debt. The company's liquidity risk is rated as medium, and while dilution risk is currently low, any future capital raising could change this. The company's reliance on a single business segment and geographic concentration in Europe also pose concentration risks. Recent events, such as the latest financial filings and analyst reports, indicate a stable but cautious outlook for Siegfried. The company's financial performance has been consistent, but there are no major new developments that would significantly alter its trajectory.

30-day price · SFZN+3.85 (+5.0%)
Low$75.70High$85.00Close$80.25As of22 May, 00:00 UTC
Profile
CompanySiegfried Holding AG
TickerSFZN.S
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Siegfried Holding AG is a Swiss pharmaceutical company that develops, produces, and markets generic and branded pharmaceutical products, primarily in the European market.

Classification. Siegfried is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Siegfried's capital structure is relatively balanced, with a debt-to-equity ratio of 0.51, indicating moderate leverage. The company maintains a current ratio of 2.0, suggesting it has sufficient short-term liquidity to cover its obligations. However, its free cash flow of CHF 15.04 million is relatively low compared to its operating cash flow of CHF 228.16 million, indicating that capital expenditures are consuming a significant portion of its operating cash. In terms of profitability, Siegfried's return on equity (ROE) of 14.95% and return on assets (ROA) of 7.83% are strong, but they should be compared to the industry median to determine relative performance. The company's gross profit margin of 26.66% (CHF 353.99 million gross profit on CHF 1.33 billion revenue) is a key indicator of its pricing power and cost control. Siegfried's operating margin of 16.85% (CHF 223.76 million operating income) is also robust, but again, a comparison to industry peers is necessary to assess its competitive position. Geographically, Siegfried's revenue is concentrated in Europe, with no specific breakdown provided in the available data. The company's exposure to this region may present both opportunities and risks, particularly in light of regulatory changes and currency fluctuations. Siegfried operates in a single business segment, which simplifies its operations but also means that its performance is entirely dependent on the pharmaceuticals market. Looking ahead, Siegfried's growth trajectory is expected to be modest, with no specific numeric deltas provided for the current or next fiscal year. The company's capital expenditures of CHF 231.47 million are a significant outflow, which may impact its ability to reinvest in growth opportunities. Analysts have a generally positive outlook, with a mean recommendation of 2.10 (on a scale from 1 to 5) and a mean price target of CHF 104.00. Siegfried faces several risk factors, including liquidity concerns due to its negative net cash position after subtracting total debt. The company's liquidity risk is rated as medium, and while dilution risk is currently low, any future capital raising could change this. The company's reliance on a single business segment and geographic concentration in Europe also pose concentration risks. Recent events, such as the latest financial filings and analyst reports, indicate a stable but cautious outlook for Siegfried. The company's financial performance has been consistent, but there are no major new developments that would significantly alter its trajectory.
Key takeaways
  • Siegfried maintains a strong ROE of 14.95% and ROA of 7.83%, indicating solid profitability.
  • The company's debt-to-equity ratio of 0.51 suggests moderate leverage, but its negative net cash position raises liquidity concerns.
  • Siegfried's free cash flow is low at CHF 15.04 million, with significant capital expenditures consuming a large portion of operating cash.
  • Analysts have a generally positive outlook, with a mean recommendation of 2.10 and a mean price target of CHF 104.00.
  • The company's geographic and business segment concentration presents both opportunities and risks.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCHF
Revenue$1.33B
Gross profit$354.0M
Operating income$223.8M
Net income$168.7M
R&D
SG&A
D&A
SBC
Operating cash flow$228.2M
CapEx-$231.5M
Free cash flow$15.0M
Total assets$2.15B
Total liabilities$1.03B
Total equity$1.13B
Cash & equivalents$103.1M
Long-term debt$575.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.13B
Net cash-$472.1M
Current ratio2.0
Debt/Equity0.5
ROA7.8%
ROE14.9%
Cash conversion1.4%
CapEx/Revenue-17.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricSFZNActivity
Op margin16.9%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin12.7%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin26.7%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-17.4%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity51.0%25.0% medp25 3.8% · p75 63.3%above median
Observations
IR observations
Mean price target104.00 CHF
Median price target105.00 CHF
High price target126.00 CHF
Low price target85.00 CHF
Mean recommendation2.10 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count5.00
Hold count3.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate4.02 CHF
Last actual EPS3.84 CHF
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-23 14:01 UTC#9bfcc538
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 09:42 UTCJob: efc204f7